Japan approves world-first oncolytic virus therapy for esophageal cancer

Japanese regulators have authorized the first-ever oncolytic virus therapy specifically targeting esophageal cancer, marking a significant shift in oncology treatment protocols. While the long-term efficacy and potential side-effect profile remain to be validated in broader clinical practice, this approval establishes a new precedent for viral-based cancer interventions.